Cybin Delivers Highest Dose Of Psilocybin Analog In Phase 2 For Major Depression

Clinical-stage psychedelics biotech Cybin CYBN has completed enrollment in its Phase 2 study of novel deuterated psilocybin analog CYB003 for the potential treatment of Major Depressive Disorder (MDD.) All participants in the sixth and final cohort have reportedly received at least one dose…#cybincybn #phase2 #mdd #cyb003 #fda #cybin #phase3 #embark #gmp #dougdrysdale
Source: Reuters: Health - Category: Consumer Health News Source Type: news